Tweet Tolebrutinib inhibited clinical non-relapsing secondary progressive MS and thus became the first drug to do this. However whilst it showed a clinical slowing of disability, it failed to have benefit in other measures. More recently a trial was done in primary progressive MS and…
Hugh Grant has a famous rant about the unbearability of slow walkers. From road-raging speed demons to travelers rushing to board airplanes, most of us recognize the simmering irritation that comes from being slowed down by someone else. Impatience is still a socially acceptable emotion…
Tweet Natalizumab is typically given as 300mg intravenous infusion every month, as the patent life of natalizumab expired a new route was developed and that is subcutaneous or under the skin. It is whacked in a lot quicker and may be delivered at home. This…
It has been a little while since I posted. Honestly, the only reason I haven’t posted is that I have been reading and trying my best to avoid Christmas. I am unsure why, but I found it nearly impossible to get in the holiday spirit this year. Regardless of…
Throughout 2025, the team at Multiple Sclerosis News Today brought our readers the latest advances and updates in research related to multiple sclerosis (MS). Below are the top 10 most-read news stories we published this year. We look forward to continuing to serve the MS…
Tweet A few years ago we had the comment was will the real MS stand up and the suggestion that there were distinct processes where the immune system enters the CNS to drive the damage and the other process that the damage is caused by…
Featuring Barry A. Hendin, MD MSAA’s Chief Medical Officer Barry Hendin, MD Question: What should care partners do if they suspect depression in their loved one with MS, and what are the treatment options? Answer: Like other medical illnesses, depression … Continue reading → Source:…
After months of delay, the U.S. Food and Drug Administration (FDA) has rejected Sanofi‘s application seeking approval of tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (MS). While Sanofi announced earlier this month that the decision was likely to be delayed…
The hardest part of my Multiple Sclerosis Rituxan infusion isn’t the struggle to find a plump vein for an IV placement, or the five hours Dan and I spend in the infusion center, or even the fatigue that follows. The hardest part is the dose…
Tweet This work was done and completed years ago and the take home message is that the results weren’t good enough of it to be developed. Lingo-1 is part of the pathway that prevents nerve regeneration , but it was also reported to inhibit remyelination.…